Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicentre, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Minoxidil Sublingual (SL) Tablet (2.5 mg) Twice Daily (BID) in the Treatment of Male Androgenetic Alopecia (AGA) in Adults

NCT06924632 is registered in ClinicalTrials.gov with Samson Clinical Operations Pty Ltd as lead sponsor.

NCT NCT06924632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06924632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicentre, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Minoxidil Sublingual (SL) Tablet (2.5 mg) Twice Daily (BID) in the Treatment of Male Androgenetic Alopecia (AGA) in Adults
Lead sponsor
Samson Clinical Operations Pty Ltd
Phase
Phase 3
Overall status
Completed
Start date
July 14, 2025
Completion date
May 15, 2026
Enrollment
142 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

androgenetic alopecia, male pattern baldness